Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL2030782 | 0.98 | ESR1 (0.51) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8029809 | 0.89 | SLC18A3 (0.56) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8029813 | 0.89 | SLC18A3 (0.56) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL26999319 | 0.89 | SLC18A3 (0.56) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16578703 | 0.82 | ESR2 (0.54) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7969541 | 0.82 | SLC18A3 (0.49) | ESR1ESR2CYP3A4CYP2C9 | |
| SCHEMBL7969540 | 0.82 | SLC18A3 (0.49) | ESR1ESR2CYP3A4CYP2C9 | |
| SCHEMBL10177735 | 0.81 | HTR2C (0.44) | — | |
| SCHEMBL12245511 | 0.81 | ESR2 (0.67) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10177698 | 0.81 | HTR2C (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106560470-A | Oxapium iodide preparation method | 平光制药股份有限公司 | 2017-04-12 | — | — | CN | claimed |
| CN-106560470-A | Oxapium iodide preparation method | 平光制药股份有限公司 | 2017-04-12 | — | — | CN | disclosed |
| US-20120053164-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053164-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | CCR2, CCR1, CCR5 | ESR1 1016/4885ESR2 536/4885CYP3A4 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.